Across TCGA pan-cancer cohorts, IGHV3-23 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of IGHV3-23’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where IGHV3-23 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types IGHV3-23 is over-expressed in tumor, although a few such as HNSC and LUAD show the opposite, repressed pattern.

HNSC, LUAD, and LSCC are the cancer types where IGHV3-23 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IGHV3-23 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	−0.940	<.001	8	view →
LUAD	Female	III,IV	−0.930	<.001	8	view →
LSCC	Male	All	−0.645	<.001	7	view →
COAD	All	All	−0.515	.024	4	view →
CCRCC	All	All	+0.319	.004	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: IGHV3-23 RNA expression & survival · all IGHV3-23 data types